Oncotelic Therapeutics, Inc. (OTCQB: OTLC) has announced the publication of a peer-reviewed study in Biomedicines demonstrating how its AI-powered PDAOAI platform helped identify a four-gene prognostic signature in hepatocellular carcinoma (HCC), the most common form of liver cancer. The study, published Oct. 23, 2026, used Partitioned Literature Aggregation (PLA), Oncotelic's patented algorithm running on PDAOAI, alongside gene-expression and survival analyses to pinpoint four genes: FKBP1A, EIF4E, RRAGC and PPARGC1A. The signature's association with patient survival was independently validated in a Japanese HCC cohort of 203 patients, lending credibility to the findings and suggesting the signature could serve as a reliable prognostic tool.
The research has direct implications for clinical trial design. According to the announcement, the findings support patient stratification for trials of Sapu003, an intravenous formulation of everolimus. By identifying patients most likely to benefit based on their genetic profile, Oncotelic aims to improve the efficiency and success rate of its drug development efforts. This approach aligns with broader trends in oncology toward precision medicine, where treatments are tailored to individual patients' molecular characteristics.
Oncotelic Chief Business Officer Saran Saund presented the research approach during an Oct. 22 keynote at the 22nd Drug Discovery Strategic Summit in California. The company highlighted the potential of partitioned AI investigations to uncover testable biological hypotheses and accelerate drug discovery. Oncotelic plans to expand PDAOAI toward a target scale of approximately 100 billion biological vectors for genetic and protein research, a significant increase that could enhance the platform's ability to generate insights from vast biological data.
Through its BIO REBOOT initiative, Oncotelic invites researchers and development teams to submit projects for potential funding and support in validation, formulation, regulatory planning and clinical development, subject to scientific review and available resources. This initiative could foster collaboration and accelerate the translation of AI-derived hypotheses into viable therapies, benefiting the broader biotech ecosystem.
The full press release can be viewed at https://ibn.fm/ctJ4J. For ongoing updates on Oncotelic Therapeutics, visit the company's newsroom at https://ibn.fm/OTLC. The announcement was distributed through BioMedWire, a specialized communications platform focused on biotechnology and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and other services. For more information, visit www.BioMedWire.com.
